170 related articles for article (PubMed ID: 35707977)
1. Usability of an application device for nabiximols oromucosal spray in patients with upper limb impaired multiple sclerosis.
Creta A; Gilio L; Centonze D; Fantozzi R
Neurodegener Dis Manag; 2022 Aug; 12(4):195-201. PubMed ID: 35707977
[TBL] [Abstract][Full Text] [Related]
2. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
[TBL] [Abstract][Full Text] [Related]
3. Effect of nabiximols on Goal Attainment Scale scores in patients with treatment-resistant multiple sclerosis spasticity.
Paul F; Silván CV
Neurodegener Dis Manag; 2021 Apr; 11(2):143-153. PubMed ID: 33641348
[TBL] [Abstract][Full Text] [Related]
4. Application device for THC:CBD oromucosal spray in the management of resistant spasticity: pre-production testing.
Montero-Escribano P; Vila Silván C
Expert Rev Med Devices; 2019 Sep; 16(9):835-840. PubMed ID: 31393179
[No Abstract] [Full Text] [Related]
5. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
Carod-Artal FJ; Adjamian P; Vila Silván C; Bagul M; Gasperini C
Expert Rev Neurother; 2022 Jun; 22(6):499-511. PubMed ID: 35582858
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
Nicholas J; Lublin F; Klineova S; Berwaerts J; Chinnapongse R; Checketts D; Javaid S; Steinerman JR
Mult Scler Relat Disord; 2023 Jul; 75():104745. PubMed ID: 37209500
[TBL] [Abstract][Full Text] [Related]
7. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity.
Flachenecker P; Henze T; Zettl UK
Eur Neurol; 2014; 71(5-6):271-9. PubMed ID: 24525548
[TBL] [Abstract][Full Text] [Related]
8. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
Grimaldi AE; De Giglio L; Haggiag S; Bianco A; Cortese A; Crisafulli SG; Monteleone F; Marfia G; Prosperini L; Galgani S; Mirabella M; Centonze D; Pozzilli C; Castelli L
PLoS One; 2019; 14(7):e0219670. PubMed ID: 31361750
[TBL] [Abstract][Full Text] [Related]
9. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
Meuth SG; Henze T; Essner U; Trompke C; Vila Silván C
Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
[No Abstract] [Full Text] [Related]
10. Evidence-based management of multiple sclerosis spasticity with nabiximols oromucosal spray in clinical practice: a 10-year recap.
Chan A; Silván CV
Neurodegener Dis Manag; 2022 Jun; 12(3):141-154. PubMed ID: 35377770
[TBL] [Abstract][Full Text] [Related]
11. Review of Available Data for the Efficacy and Effectiveness of Nabiximols Oromucosal Spray (Sativex®) in Multiple Sclerosis Patients with Moderate to Severe Spasticity.
Conte A; Vila Silván C
Neurodegener Dis; 2021; 21(3-4):55-62. PubMed ID: 34731865
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of nabiximols oromucosal spray: a review of real-world experience in observational studies, registries, and case reports.
Prieto González JM; Vila Silván C
Expert Rev Neurother; 2021 May; 21(5):547-558. PubMed ID: 33749480
[TBL] [Abstract][Full Text] [Related]
13. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
Arroyo González R
Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
[TBL] [Abstract][Full Text] [Related]
14. Sativex
Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
[TBL] [Abstract][Full Text] [Related]
15. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
[TBL] [Abstract][Full Text] [Related]
16. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P; Trojano M
Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
[TBL] [Abstract][Full Text] [Related]
17. Effects of Sativex
Dykukha I; Essner U; Schreiber H; Raithel LM; Penner IK
Mult Scler Relat Disord; 2022 Dec; 68():104173. PubMed ID: 36174323
[TBL] [Abstract][Full Text] [Related]
18. Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
Mallada Frechín J
Neurodegener Dis Manag; 2018 Jun; 8(3):151-159. PubMed ID: 29851356
[TBL] [Abstract][Full Text] [Related]
19. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
Lus G; Cantello R; Danni MC; Rini A; Sarchielli P; Tassinari T; Signoriello E
Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
[TBL] [Abstract][Full Text] [Related]
20. The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
Celius EG; Vila C
Brain Behav; 2018 May; 8(5):e00962. PubMed ID: 29761015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
